The search for mutations that conjure medical superpowers has turned up people who are resistant to liver disease, even if they drink like crazy.
Big-time biotech company Regeneron Pharmaceuticals says it found people with a gene mutation that seems to leave them mostly immune to “fatty liver” disease, which is widespread in the US as a result of both alcoholism and overeating.
Now, the company says, it will partner with gene-silencing specialist Alnylam Pharmaceuticals to create medicines that mimic the effect.
Regeneron runs one of the world’s largest gene-sequencing operations in partnership with the Geisinger Health System, operator of a large hospital network.
It has the DNA code and the medical records of thousands of volunteers.
That allows the company to search for people unusually resistant to certain diseases and then determine if there’s an explanation in their DNA (see “The search for exceptional genomes”).
The search for genetic superpowers can lead quickly to new drugs, such as a powerful cholesterol-lowering medicine already being sold by Regeneron.
This time, Regeneron scoured the DNA, blood levels, and electronic records of 46,544 volunteers to look for links to liver damage.
They zeroed in on a gene called HSD17B13. They found that folks who lack a working copy of this gene had a 73 percent lower chance of cirrhosis due to drinking, and half as big a chance of other types of cirrhosis.
How the protective effect works isn’t entirely clear. But the two biotech companies say they will now try to create a drug to treat fatty-liver disease.
About a quarter of Americans suffer from the condition, according to a report published by the Regeneron scientists in the New England Journal of Medicine on March 21.
Fatty liver is chronic and not always dangerous. The biotech companies say they are looking to treat a specific type called nonalcoholic steatohepatitis, or NASH, which is more likely to lead to liver failure.
The liver problem is linked to being overweight, so losing weight can slow it down. For those who can’t shed the pounds, Regeneron may eventually have a superpower in a vial.
These scientists used CRISPR to put an alligator gene into catfish
The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.
Next up for CRISPR: Gene editing for the masses?
Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.
CRISPR for high cholesterol: 10 Breakthrough Technologies 2023
New forms of the gene-editing tool could enable treatments for common diseases.
An ALS patient set a record for communicating via a brain implant: 62 words per minute
Brain interfaces could let paralyzed people speak at almost normal speeds.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.